News for Exelixis, Inc. (EX9.DE)

On May 21, 2025, Tomas Heyman, Director at Exelixis Inc (EXEL), sold 4,544 shares of the company, as reported in a SEC Filing. Following this transaction, the i

Summary Exelixis Inc (EXEL) has released results from an expansion cohort of the phase 1b/2 STELLAR-002 trial, evaluating the efficacy of zanzalintinib in combi

[url="]Exelixis, Inc.[/url] (Nasdaq: EXEL) today announced results from an expansion cohort of the phase 1b/2 STELLAR-002 trial evaluating zanzalintinib in com

On March 31, 2025, Caligan Partners LP (Trades, Portfolio), a New York-based investment firm, expanded its position in Y-mAbs Therapeutics Inc by acquiring an a

In the current market session, Exelixis Inc. EXEL stock price is at $45.07, after a 2.57% drop. However, over the past month, the company's stock went up by 26....

Exelixis (EXEL), a biotechnology company primarily focused on cancer treatment development, received positive attention as Citigroup analyst David Lebowitz main

Guggenheim's analyst, Michael Schmidt, has adjusted the firm's price target for Exelixis (EXEL), moving it up to $45 from $42. This action is supported by an op

We recently published a list of These 10 Firms Blowing Up by Double Digits Today.

Exelixis delivers a strong Q1 performance with raised 2025 guidance, robust Cabometyx sales, and share buybacks. Read the latest EXEL stock analysis here.

On May 14, 2025, RBC Capital reaffirmed its positive outlook on Exelixis (EXEL) by maintaining its "Outperform" rating. The assessment was delivered by analyst

Exelixis, Inc. (NASDAQ:EXEL) Q1 2025 Earnings Conference Call May 13, 2025 5:00 PM ETCompany ParticipantsSusan Hubbard - Executive Vice President, Public...

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2025, provided an update on progress toward achieving key corporate obj

We recently published a list of 15 Best Stocks to Buy According to Jim Simons’ Renaissance Technologies In this article, we are going to take a look at where Exelixis, Inc. (NASDAQ:EXEL) stands against other best stocks to buy according to Jim Simons’ Renaissance Technologies. Even after his passing in 2024, billionaire investor and mathematician […]

We recently published a list of 15 Best Stocks to Buy According to Jim Simons’ Renaissance Technologies In this article, we are going to take a look at where Exelixis, Inc.

We recently compiled a list of the 20 Large-Cap Stocks Insiders and Short Sellers Are Dumping Like Crazy. In this article, we are going to take a look at where Exelixis, Inc.

On March 31, 2025, BlackRock, Inc. (Trades, Portfolio) executed a significant transaction involving Exelixis Inc., a biopharmaceutical company. The firm reduced

Exelixis, Inc. (EXEL) will release its Q1 2025 financial results on May 13, 2025. A conference call and webcast will follow at 5:00 p.m. ET / 2:00 p.m.

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a look at where Exelixis, Inc. (NASDAQ:EXEL) stands against other most profitable biotech stocks to buy right now. With improved market conditions, innovative breakthroughs, and more investor interest, the biotechnology industry is […]

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a look at where Exelixis, Inc.